Children’s Hospital Colorado has been ranked among the top pediatric oncology programs in the United States for more than 10 consecutive years by US News and World Report. Children's Colorado physicians are national leaders in developing and executing clinical trials and linked correlative biology studies.
The pediatric neurooncology program is also nationally recognized, and Children's Colorado is the primary site of referral for children with brain cancer in the Rocky Mountain region. Through the development of one of the largest national pediatric brain tumor tissue banks, basic and translational cancer researchers have focused on the discovery of new prognostic markers and drug targets.
Children's Colorado's Experimental Therapeutics Program is the only program in the Rocky Mountain region that provides comprehensive early phase clinical trials for children with cancer. The Pediatric Oncology Experimental Therapeutics Investigators Consortium develops early phase clinical trials of targeted therapies that provide children and adolescents with refractory cancer with access to new treatments and modalities only available at a few highly select academic institutions around the country. The program was the first to open 12 different Phase I/II trials in the world, and first in the world to treat children in several different “First in Pediatric“ studies.
The majority of the research in pediatric oncology is translational in nature and carried out by physician-scientists who are divided among the CU Cancer Center Molecular Oncology and Developmental Therapeutic programs. The CU Cancer Center and Children's Colorado have also established a cancer survivorship clinic for adult survivors of childhood cancer.
Children's Hospital Colorado
Center for Cancer and Blood Disorders
Consortium Advisory Committee Representative
Stephen Hunger, MD
Chief for Cancer and Blood Disorders